WCM
BCRX icon

Wedge Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Wedge Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.62M Buy
434,114
+53,313
+14% +$502K 0.06% 234
2026
Q2 		$3.81M Buy
+380,801
New +$3.44M 0.06% 233

Other funds holding BCRX

DA
Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
MBI
May Barnhard Investments Bethesda, Maryland $243M AUM 13.89% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $552M AUM 32.44% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
RF
RHS Financial San Francisco, California $296M AUM 17.24% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Wedge Capital Management's BCRX Position: Q3 2026 in Review

Wedge Capital Management increased its BioCryst Pharmaceuticals (BCRX) stake by 14% in Q3 2026, buying an estimated $502K and bringing the position to 434,114 shares worth $3.62M. The position accounts for 0.06% of the portfolio, ranked #234.

Wedge Capital Management first reported a position in BCRX in Q2 2026 and has held it in 2 quarters since. The position peaked at $3.81M in Q2 2026. 11 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • Wedge Capital Management held 434,114 shares of BioCryst Pharmaceuticals worth $3.62M as of Q3 2026.
  • Wedge Capital Management bought 53,313 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $502K.
  • BioCryst Pharmaceuticals made up 0.06% of Wedge Capital Management's portfolio in Q3 2026, its #234 holding.
  • Wedge Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • Wedge Capital Management's BioCryst Pharmaceuticals position peaked at $3.81M in Q2 2026.
  • 11 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Wedge Capital Management's 13F filing for Q3 2026, filed 13 Oct 2026.